News and Updates

The EU has approved Camizestrant as a first-line treatment for ER-positive, HER2-negative advanced breast cancer when combined with a CDK4/6 inhibitor.

Kalshi is now allowing prediction markets for FDA drug approvals and clinical trial outcomes. Discover how this shift impacts biotech and market forecasting.

Arcus Biosciences and Summit Therapeutics have launched a clinical partnership to test novel cancer treatment combinations for solid tumors.

Discover how AI-driven biomarker stratification is transforming clinical trial enrollment, reducing screen failures, and accelerating drug development.

Spryte Medical has finished patient enrollment for the INSYTE trial. Discover the key implications for this medical device and future clinical standards.

BostonGene and Kyoto University have partnered to advance precision oncology using AI-driven molecular profiling and multi-omics analysis.

A groundbreaking discovery in multiple myeloma research reveals a new therapeutic target, offering hope for treatment-resistant patients. Learn more.

The Phase 2b trial for the TB vaccine candidate MTBVAC has reached full enrollment, marking a major step toward a new, effective tuberculosis prevention.

Health Canada has authorized a Phase II/III trial for Thykamine in children. Learn how this study impacts pediatric inflammatory disease treatment.

Innate Pharma has finished dose-escalation enrollment for IPH4502, a Nectin-4 targeting ADC. Learn about this milestone in solid tumor clinical research.